vs
Side-by-side financial comparison of Fabrinet (FN) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Fabrinet is the larger business by last-quarter revenue ($1.1B vs $708.5M, roughly 1.6× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 9.9%, a 9.1% gap on every dollar of revenue. On growth, Fabrinet posted the faster year-over-year revenue change (35.9% vs 32.0%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $-5.3M). Over the past eight quarters, Fabrinet's revenue compounded faster (24.4% CAGR vs 17.7%).
FabrinetFNEarnings & Financial Report
Below is a list of companies having stocks that are included in the S&P MidCap 400 stock market index. The index, maintained by S&P Dow Jones Indices, comprises the common stocks of 400 mid-cap, mostly American, companies. Although called the S&P 400, the index sometimes contains more than 400 stocks when it includes two or more share classes of stock from one of its component companies.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
FN vs MEDP — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $708.5M |
| Net Profit | $112.6M | $135.1M |
| Gross Margin | 12.2% | — |
| Operating Margin | 10.1% | 21.6% |
| Net Margin | 9.9% | 19.1% |
| Revenue YoY | 35.9% | 32.0% |
| Net Profit YoY | 30.0% | 15.5% |
| EPS (diluted) | $3.11 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $708.5M | ||
| Q3 25 | $978.1M | $659.9M | ||
| Q2 25 | $909.7M | $603.3M | ||
| Q1 25 | $871.8M | $558.6M | ||
| Q4 24 | $833.6M | $536.6M | ||
| Q3 24 | $804.2M | $533.3M | ||
| Q2 24 | $753.3M | $528.1M | ||
| Q1 24 | $731.5M | $511.0M |
| Q4 25 | $112.6M | $135.1M | ||
| Q3 25 | $95.9M | $111.1M | ||
| Q2 25 | $87.2M | $90.3M | ||
| Q1 25 | $81.3M | $114.6M | ||
| Q4 24 | $86.6M | $117.0M | ||
| Q3 24 | $77.4M | $96.4M | ||
| Q2 24 | $81.1M | $88.4M | ||
| Q1 24 | $80.9M | $102.6M |
| Q4 25 | 12.2% | — | ||
| Q3 25 | 11.9% | — | ||
| Q2 25 | 12.2% | — | ||
| Q1 25 | 11.7% | — | ||
| Q4 24 | 12.1% | — | ||
| Q3 24 | 12.3% | — | ||
| Q2 24 | 12.3% | — | ||
| Q1 24 | 12.4% | — |
| Q4 25 | 10.1% | 21.6% | ||
| Q3 25 | 9.6% | 21.5% | ||
| Q2 25 | 9.8% | 20.9% | ||
| Q1 25 | 9.0% | 20.3% | ||
| Q4 24 | 9.5% | 23.4% | ||
| Q3 24 | 9.6% | 21.1% | ||
| Q2 24 | 9.7% | 19.9% | ||
| Q1 24 | 9.7% | 20.4% |
| Q4 25 | 9.9% | 19.1% | ||
| Q3 25 | 9.8% | 16.8% | ||
| Q2 25 | 9.6% | 15.0% | ||
| Q1 25 | 9.3% | 20.5% | ||
| Q4 24 | 10.4% | 21.8% | ||
| Q3 24 | 9.6% | 18.1% | ||
| Q2 24 | 10.8% | 16.7% | ||
| Q1 24 | 11.1% | 20.1% |
| Q4 25 | $3.11 | $4.65 | ||
| Q3 25 | $2.66 | $3.86 | ||
| Q2 25 | $2.41 | $3.10 | ||
| Q1 25 | $2.25 | $3.67 | ||
| Q4 24 | $2.38 | $3.67 | ||
| Q3 24 | $2.13 | $3.01 | ||
| Q2 24 | $2.22 | $2.75 | ||
| Q1 24 | $2.21 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $960.8M | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2B | $459.1M |
| Total Assets | $3.3B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $960.8M | $497.0M | ||
| Q3 25 | $968.8M | $285.4M | ||
| Q2 25 | $934.2M | $46.3M | ||
| Q1 25 | $950.7M | $441.4M | ||
| Q4 24 | $934.6M | $669.4M | ||
| Q3 24 | $908.9M | $656.9M | ||
| Q2 24 | $858.6M | $510.9M | ||
| Q1 24 | $794.0M | $407.0M |
| Q4 25 | $2.2B | $459.1M | ||
| Q3 25 | $2.1B | $293.6M | ||
| Q2 25 | $2.0B | $172.4M | ||
| Q1 25 | $1.9B | $593.6M | ||
| Q4 24 | $1.8B | $825.5M | ||
| Q3 24 | $1.8B | $881.4M | ||
| Q2 24 | $1.7B | $763.6M | ||
| Q1 24 | $1.7B | $671.5M |
| Q4 25 | $3.3B | $2.0B | ||
| Q3 25 | $3.0B | $1.8B | ||
| Q2 25 | $2.8B | $1.6B | ||
| Q1 25 | $2.6B | $1.9B | ||
| Q4 24 | $2.5B | $2.1B | ||
| Q3 24 | $2.4B | $2.1B | ||
| Q2 24 | $2.3B | $1.9B | ||
| Q1 24 | $2.2B | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $46.3M | $192.7M |
| Free Cash FlowOCF − Capex | $-5.3M | $188.1M |
| FCF MarginFCF / Revenue | -0.5% | 26.6% |
| Capex IntensityCapex / Revenue | 4.6% | 0.6% |
| Cash ConversionOCF / Net Profit | 0.41× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $102.3M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $46.3M | $192.7M | ||
| Q3 25 | $102.6M | $246.2M | ||
| Q2 25 | $55.1M | $148.5M | ||
| Q1 25 | $74.2M | $125.8M | ||
| Q4 24 | $115.9M | $190.7M | ||
| Q3 24 | $83.2M | $149.1M | ||
| Q2 24 | $83.1M | $116.4M | ||
| Q1 24 | $100.9M | $152.7M |
| Q4 25 | $-5.3M | $188.1M | ||
| Q3 25 | $57.3M | $235.5M | ||
| Q2 25 | $4.7M | $142.4M | ||
| Q1 25 | $45.7M | $115.8M | ||
| Q4 24 | $94.0M | $183.0M | ||
| Q3 24 | $62.9M | $138.5M | ||
| Q2 24 | $70.4M | $103.5M | ||
| Q1 24 | $87.3M | $147.2M |
| Q4 25 | -0.5% | 26.6% | ||
| Q3 25 | 5.9% | 35.7% | ||
| Q2 25 | 0.5% | 23.6% | ||
| Q1 25 | 5.2% | 20.7% | ||
| Q4 24 | 11.3% | 34.1% | ||
| Q3 24 | 7.8% | 26.0% | ||
| Q2 24 | 9.3% | 19.6% | ||
| Q1 24 | 11.9% | 28.8% |
| Q4 25 | 4.6% | 0.6% | ||
| Q3 25 | 4.6% | 1.6% | ||
| Q2 25 | 5.5% | 1.0% | ||
| Q1 25 | 3.3% | 1.8% | ||
| Q4 24 | 2.6% | 1.4% | ||
| Q3 24 | 2.5% | 2.0% | ||
| Q2 24 | 1.7% | 2.4% | ||
| Q1 24 | 1.9% | 1.1% |
| Q4 25 | 0.41× | 1.43× | ||
| Q3 25 | 1.07× | 2.22× | ||
| Q2 25 | 0.63× | 1.65× | ||
| Q1 25 | 0.91× | 1.10× | ||
| Q4 24 | 1.34× | 1.63× | ||
| Q3 24 | 1.07× | 1.55× | ||
| Q2 24 | 1.02× | 1.32× | ||
| Q1 24 | 1.25× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FN
| Optical Communications | $832.6M | 73% |
| Non Optical Communications | $300.3M | 27% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
